References
- Chen C, Gardete S, Jansen RS, Shetty A, Dick T, Rhee KY, Dartois V. 2018. Verapamil targets membrane energetics in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 62(5):e02107-17.
- Gui Z, Luo F, Yang Y, Shen C, Li S, Xu J. 2017. Oridonin inhibition and miR200b3p/ZEB1 axis in human pancreatic cancer. Int J Oncol. 50(1):111–120.
- Guo L, Cui Y, Hao K. 2018. Effects of glycyrrhizin on the pharmacokinetics of asiatic acid in rats and its potential mechanism. Pharm Biol. 56(1):119–123.
- He W, Yang K, Fan L, Lv Y, Jin Z, Zhu S, Qin C, Wang Y, Yin L. 2015. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability. Int J Pharm. 495(1):9–18.
- Huang Y, Zhao J, Jian W, Wang G. 2018. Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism. Xenobiotica. 48(8):839–844.
- Jin Y, Tian T, Ma Y, Xu H, Du Y. 2015. Simultaneous determination of ginsenoside Rb1, naringin, ginsenoside Rb2 and oridonin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study after oral administration of Weifuchun tablet. J Chromatogr B Analyt Technol Biomed Life Sci. 1000:112–119.
- Li W, Ma L. 2019. Synergistic antitumor activity of oridonin and valproic acid on HL-60 leukemia cells. J Cell Biochem. 120(4):5620–5627.
- Liu L, Sun S, Li X. 2018. In vitro characterization of the intestinal absorption mechanism of dihydromyricetin in Caco-2 cell model. Lat Am J Pharm. 37:908–913.
- Park H, Jeong YJ, Han NK, Kim JS, Lee HJ. 2018. Oridonin enhances radiation-induced cell death by promoting DNA damage in non-small cell lung cancer cells. Int J Mol Sci. 19(8):2378–2390.
- Piao Y-J, Li X, Choi J-S. 2008. Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats. Eur J Drug Metab Pharmacokinet. 33(3):159–164.
- Wang X, Zhang X, Liu F, Wang M, Qin S. 2017. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. Pharm Biol. 55(1):1863–1867.
- Wang Y, Zhu Z. 2019. Oridonin inhibits metastasis of human ovarian cancer cells by suppressing the mTOR pathway. Arch Med Sci. 15(4):1017–1027.
- Xu W, Sun J, Zhang TT, Ma B, Cui SM, Chen DW, He ZG. 2006. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol Sin. 27(12):1642–1646.
- Yan G, Zhang H, Wang W, Li Y, Mao C, Fang M, Yi X, Zhang J. 2017. Investigation of the influence of glycyrrhizin on the pharmacokinetics of celastrol in rats using LC-MS and its potential mechanism. Xenobiotica. 47(7):607–613.
- Yang J, Ren X, Zhang L, Li Y, Cheng B, Xia J. 2018. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway. Biomed Pharmacother. 100:226–232.
- Yao Z, Xie F, Li M, Liang Z, Xu W, Yang J, Liu C, Li H, Zhou H, Qu LH. 2017. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells. Cell Death Dis. 8(2):e2633.
- Zhang W, Liu M, Yang L, Huang F, Lan Y, Li H, Wu H, Zhang B, Shi H, Wu X. 2019. P-glycoprotein inhibitor tariquidar potentiates efficacy of astragaloside IV in experimental autoimmune encephalomyelitis mice. Molecules. 24(3):561–575.
- Zhang LQ, Xu XS, Wan Y, Song SD, Wang RT, Chen W, Wang ZX, Chang HL, Wei JC, Dong YF, et al. 2015. Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma. World J Gastroenterol. 21(4):1243–1250.
- Zhou Y, Song X, Dong G. 2019. Effects of verapamil on the pharmacokinetics of puerarin in rats. Xenobiotica. 49(10):1178–1182.
- Zhu T, Howieson C, Wojtkowski T, Garg JP, Han D, Fisniku O, Keirns J. 2017. The effect of verapamil, a P-glycoprotein inhibitor, on the pharmacokinetics of peficitinib, an orally administered, once-daily JAK inhibitor. Clin Pharmacol Drug Dev. 6(6):548–555.